ANDAU

Andina Acquisition Corp. III [ANDAU] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ANDAU Stock Summary

In the News

08:11 29 Mar 2024 ANDAU

Andina Acquisition Corp. III and Stryve Foods LLC Announce Shareholder Approval of the Business Combination

– Expected Closing Date of July 20, 2021 –

10:45 29 Mar 2024 ANDAU

Andina Acquisition Corp. III and EMMAC Life Sciences Limited Announce Termination of Negotiations

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Andina Acquisition Corp. III (NASDAQ: ANDA, ANDAW, and ANDAU) (“Andina”) and EMMAC Life Sciences Limited (“EMMAC”) announce that they have today mutually terminated negotiations regarding the proposed business combination between the parties, pursuant to which EMMAC was expected to become a publicly traded company on the NASDAQ Stock Market.

10:45 29 Mar 2024 ANDAU

Andina Acquisition Corp. III Announces Adjournment of the Extraordinary General Meeting of Shareholders for Approving an Extension of the Deadline Related to Consummating its Initial Business Combination

NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Andina Acquisition Corp. III (NASDAQ: ANDA, ANDAW, and ANDAU) (“Andina” or the “Company”) today announced that the Company's shareholders have voted to adjourn the meeting for the consideration of extending the date by which Andina must consummate a business combination from October 31, 2020 (or December 31, 2020 if Andina has executed a definitive agreement for a business combination by October 31, 2020) to January 31, 2021 (or April 30, 2021 if Andina has executed a definitive agreement for a business combination by January 31, 2021) (the “Proposed Extension”) to a later date or dates to be determined by the Company's board of directors. Upon shareholders' approval of the adjournment, the Company's board of directors has determined to adjourn the extraordinary general meeting of its shareholders to vote on the Proposed Extension to 4:00 p.m. Eastern Time on Friday, October 30, 2020.

06:00 29 Mar 2024 ANDAU

Andina Acquisition Corp. III Announces Intention to Adjourn Extraordinary General Meeting of Shareholders for Approving an Extension of the Deadline Related to Consummating its Initial Business Combination

NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Andina Acquisition Corp. III (NASDAQ: ANDA, ANDAW, and ANDAU) (“Andina” or the “Company”) today announced that the Company's board of directors has determined to postpone the vote by its shareholders on extending the date by which Andina must consummate a business combination from October 31, 2020 (or December 31, 2020 if Andina has executed a definitive agreement for a business combination by October 31, 2020) to January 31, 2021 (or April 30, 2021 if Andina has executed a definitive agreement for a business combination by January 31, 2021) (the “Proposed Extension”).

11:33 29 Mar 2024 ANDAU

Andina Acquisition Corp. III and EMMAC Life Sciences Limited Provide Update on Status Towards Signing Business Combination Agreement

EMMAC is the Largest Independent European Cannabis Company with Low-Cost Cultivation, EU-GMP Manufacturing and Processing, and an Import / Distribution Network in all Key European Markets EMMAC is the Largest Independent European Cannabis Company with Low-Cost Cultivation, EU-GMP Manufacturing and Processing, and an Import / Distribution Network in all Key European Markets

06:00 29 Mar 2024 ANDAU

EMMAC Life Sciences Group Secures GDP licence for Swiss pharmaceutical entity, EMMAC SAGL Approved to import, distribute and export medicinal products for domestic, EU and international markets

LONDON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- EMMAC Life Sciences Group (”EMMAC” or the “Group” or the “Company”), Europe’s largest independent cannabis company, is pleased to announce that EMMAC SAGL, the Group’s pharmaceutical entity in  Switzerland, has secured its Good Distribution Practice (“GDP”) licence for the distribution of medicinal products. EMMAC now has the ability to import, distribute and export medicinal products, including medical cannabis, for the domestic Swiss, EU and international markets.  EMMAC currently holds multiple research, cultivation and GMP licences across its vertically integrated business in Europe, which is experiencing increasing demand for premium-quality medical cannabis products. The European medical cannabis market is predicted to be worth in excess of $8 billion by 2023.1Antonio Costanzo, CEO of EMMAC, said: “This is another important milestone for EMMAC and one that positions us well to meet the requirements of the domestic Swiss market as regulation evolves, and caters to the growing demand from international markets for high-quality medical cannabis. We continue to execute at pace, realising our vision of establishing EMMAC as Europe’s largest independent cannabis company, and shaping the future of medical cannabis.”On 22 July 2020, EMMAC announced the Company had signed a non-binding letter of intent related to a business combination with Andina Acquisition Corp. III (NASDAQ: ANDA, ANDAW, and ANDAU) (“Andina”), pursuant to which EMMAC would become a publicly traded company on the NASDAQ Stock Exchange with EMMAC’s shareholders rolling over all of their equity in EMMAC into the combined public company. As consideration for the transaction, it is anticipated that the current EMMAC shareholders would collectively own a majority of the equity of the combined public company.___________ 1 Source: Brightfield Group – European CBD and Cannabis Market 2019 Report &  Canaccord (2018) + Cowen Data for U.S. CBD Market Applied to Europe (2023)About EMMAC Life Sciences Group EMMAC Life Sciences Group is Europe’s largest independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it. For more information about EMMAC, please visit https://www.emmac.com/Contact: For scientific enquiries please contact research@emmac.com For general enquiries please contact info@emmac.com or visit www.emmac.comMedia enquiries:Buchanan   Henry Harrison-Topham / Jamie Hooper / Ariadna PeretzTel: +44 (0) 20 7466 5000   emmac@buchanan.uk.com www.buchanan.uk.com       CAUTIONARY STATEMENT All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

06:00 29 Mar 2024 ANDAU

EMMAC Life Sciences Group (”EMMAC” or the “Group” or the “Company”) Medalchemy receives licence for cultivation of medical cannabis

Spanish EU GMP Facility now has licences to cultivate, extract and manufacture cannabis extract  EMMAC now licensed to cultivate medical cannabis in Portugal and Spain  LONDON, July 28, 2020 (GLOBE NEWSWIRE) -- EMMAC Life Sciences Group, Europe’s largest independent cannabis company, is pleased to announce that Medalchemy, the Group’s Good Manufacturing Practice (“GMP”) certified manufacturing site in Alicante, Spain has secured approval from the Spanish Health Authorities (“AEMPS”) to cultivate medical cannabis. Medalchemy now has fully integrated cannabis supply facilities, with a licence to grow medical cannabis commercially as well as extract and manufacture cannabis extract as an active pharmaceutical ingredient (“API”).EMMAC holds two medical cannabis cultivation licences, one in Spain, at Medalchemy, and the second in Portugal, at its primary cultivation site Terra Verde, which in 2020 has produced and exported c.2 tonnes of medical cannabis flower. EMMAC now holds multiple medical cannabis licences in 4 countries across Europe.Antonio Costanzo, CEO of EMMAC, said: “This latest licence to cultivate medical cannabis at our EU-GMP Facility in Alicante strengthens EMMAC’s position as the leading European independent cannabis company with two culitivation facilities and an alternative point of supply for our business. With full control of our supply chain we are able to ensure a consistent, reliable and high-quality product that our growing customer base can trust. As European legislation quickly evolves to reflect the growing body of medical evidence regarding the benefits of medical cannabis, EMMAC’s integrated business model positions it well to capitalise on the high-growth potential of this valuable market.”Last week, EMMAC announced that the Company signed a non-binding letter of intent related to a business combination with Andina Acquisition Corp. III (NASDAQ: ANDA, ANDAW, and ANDAU) (“Andina”), pursuant to which EMMAC would become a publicly traded company on the NASDAQ Stock Market with EMMAC’s shareholders rolling over all of their equity in EMMAC into the combined public company. As consideration for the transaction, it is anticipated that the current EMMAC shareholders would collectively own a majority of the equity of the combined public company.About EMMAC Life Sciences Group EMMAC Life Sciences Group is Europe’s largest independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it. For more information about EMMAC, please visit https://www.emmac.com/Contact: For scientific enquiries please contact research@emmac.com For general enquiries please contact info@emmac.com or visit www.emmac.comMedia enquiries:Buchanan  Henry Harrison-Topham / Jamie Hooper / Ariadna PeretzTel: +44 (0) 20 7466 5000 emmac@buchanan.uk.comwww.buchanan.uk.com CAUTIONARY STATEMENT All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

12:31 29 Mar 2024 ANDAU

Andina Acquisition Corp. III and EMMAC Life Sciences Limited to Host Joint Zoom Webcast and Conference Call Today at 11:00 AM to Discuss Non-Binding Letter of Intent for Business Combination

EMMAC is the Largest Independent European Cannabis Company with Low-Cost Cultivation, EU-GMP Manufacturing and Processing, and an Import / Distribution Network in all Key European MarketsNEW YORK and LONDON, July 24, 2020 (GLOBE NEWSWIRE) -- Andina Acquisition Corp. III (NASDAQ: ANDA, ANDAW, and ANDAU) (“Andina”) and EMMAC Life Sciences Limited (“EMMAC”) jointly announced that the companies will host a Zoom webcast and conference call at 11:00 AM ET today to discuss their non-binding letter of intent (the “LOI”) for a business combination, pursuant to which EMMAC would become a publicly traded company on the NASDAQ Stock Market. As consideration for the transaction, it is anticipated that the current EMMAC shareholders would collectively own a majority of the equity of the combined public company. Hosting the Zoom webcast and conference call from Andina with be Chairman Luke Weil and CEO Julio A. Torres and from EMMAC will be Executive Chairman Lorne Abony, CEO Antonio Costanzo, and CFO Thomas Ellen.The Zoom webcast can be accessed via https://icrinc.zoom.us/j/98346862705 and the conference call can be accessed by dialing (301) 715-8592, passcode 98346862705Information on EMMAC can be found in an investor presentation that has been furnished by Andina to the SEC as an exhibit to a Current Report on Form 8-K, which can also be found on Andina’s website at http://www.andinaacquisition.com/ or on EMMAC’s website at https://www.emmac.com/EMMAC is Europe’s largest independent cannabis company, bringing together cutting-edge scientific research with the latest innovations in medical cannabis cultivation, extraction and production. The company is a trusted cannabis partner for the medical and wellness communities and leader in the production and supply of medical cannabis, wellness CBD, hemp, and other derivative products with large scale, low-cost, cultivation, EU-GMP manufacturing and processing, import / distribution network across all critical European markets. EMMAC has established pharmaceutical and medical cannabis manufacturing credibility and a direct-to-patient pharmacy license, multiple take-or-pay contracts for wholesale cannabis, and a strong portfolio of wellness brands and wellness products. EMMAC is also the first European cannabis company to sell and export product to Israel and will be launching white-label CBD products in the US.EMMAC has an extensive research platform spanning genetics, technology, and medical/clinical programs with Imperial College London and other leading European research centers. EMMAC’s wealth of experience, combined with a network of supply and distribution partnerships throughout Europe, mean that it is uniquely positioned to meet the rapidly growing demands of the market, led by regulatory change and the increasing demand for access to premium quality cannabis product.Completion of the business combination is subject to, among other matters, the completion of due diligence, the negotiation and execution of a definitive agreement for the business combination, satisfaction of the conditions negotiated therein and approval of the transaction by Andina stockholders. Accordingly, there can be no assurance that a definitive agreement will be entered into or the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all. Any transaction would be subject to the approval of the two companies’ boards and shareholder approvals, as well as other customary conditions.Cowen is serving as financial and capital markets advisor to Andina and Ellenoff Grossman & Schole LLP is serving as legal advisor to Andina. Stifel is serving as financial advisor to EMMAC. Winston & Strawn LLP is serving as legal advisor to EMMAC.About Andina Acquisition Corp. III Andina Acquisition Corp. III (NASDAQ: ANDA, ANDAW, and ANDAU) is a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. For information about Andina, please visit http://www.andinaacquisition.com/About EMMAC Life Sciences Limited EMMAC Life Sciences Limited is Europe’s largest independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it. For more information about EMMAC, please visit https://www.emmac.com/Additional Information and Where to Find It If a definitive agreement is entered into and in connection with the proposed transactions described herein, a full description of the terms of the transaction will be provided in a proxy statement/prospectus for Andina’s stockholders to be filed with the U.S. Securities and Exchange Commission (the “SEC”). Andina urges investors, stockholders and other interested persons to read, when available, the preliminary proxy statement/prospectus, as well as other documents filed with the SEC, because these documents will contain important information about the Company, EMMAC and the proposed business combination transaction.  The definitive proxy statement/prospectus will be mailed to stockholders of Andina as of a record date to be established for voting on the proposed transaction. Shareholders may obtain copies of the proxy statement/prospectus, when available, without charge, at the SEC’s website at www.sec.gov or by directing a request to: Andina Acquisition Corp. III, Calle 113 7-45 Torre B, Oficinia 1012, Bogota, Colombia.In addition, Andina has filed a definitive proxy statement (the “Extension Proxy Statement”) to be use at its special meeting of shareholders to approve an extension of time in which Andina must complete its initial business combination or liquidate the trust account that holds the proceeds of the Company’s initial public offering (the “Extension”).  Andina mailed the Extension Proxy Statement and other relevant documents to its shareholders of record as of July 1, 2020 in connection with the Extension.  Investors and security holders of Andina are advised to read the Extension Proxy Statement because this document contains important information about the Extension.  Shareholders are able to obtain copies of the Extension Proxy Statement, without charge, at the SEC’s website at www.sec.gov or by directing a request to: Andina Acquisition Corp. III, Calle 113 7-45 Torre B, Oficinia 1012, Bogota, Colombia.Participants in Solicitation Andina and its directors, executive officers and other members of their management and employees may be deemed to be participants in the solicitation of proxies of Andina stockholders in connection with the Extension and the potential transaction described herein under the rules of the SEC. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of Andina’s directors in the Extension Proxy Statement, which was filed with the SEC on July 6, 2020 and will also be contained in the proxy statement/prospectus relating to the proposed transaction when it is filed with the SEC.  These documents may be obtained free of charge from the sources indicated above.Non-Solicitation This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Andina, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.Forward Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. These forward-looking statements and factors that may cause such differences include, without limitation, Andina’s and EMMAC’ inability to enter into a definitive agreement with respect to the proposed business combination transaction or to complete the transactions contemplated by the non-binding letter of intent; matters discovered by the parties as they complete their respective due diligence investigation of the other; the inability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, the amount of cash available following any redemptions by Andina stockholders; the ability to meet NASDAQ's listing standards following the consummation of the transactions contemplated by the proposed business combination; costs related to the proposed business combination; expectations with respect to future operating and financial performance and growth, including when EMMAC will become cash flow positive; the timing of the completion of the proposed business combination; EMMAC’ ability to execute its business plans and strategy and to receive regulatory approvals; and other risks and uncertainties indicated from time to time in filings with the SEC, including Andina’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 under the heading “Risk Factors” and other documents of Andina filed, or to be filed, with the SEC.

11:18 29 Mar 2024 ANDAU

INTERVIEW: European Cannabis Leader EMMAC Gets Lifted Through a SPAC

EMMAC Executive Chairman Lorne Abony By Jarrett Banks EMMAC Life Sciences, Europe’s largest cannabis company, will go public through a merger with Andina Acquistion Corp. III, giving U.S. investors access to the white-hot medical cannabis sector in Europe. EMMAC signed a letter of intent to combine with the special purpose acquisition company, or SPAC, to […]

07:30 29 Mar 2024 ANDAU

European Cannabis Company EMMAC Life Sciences To Go Public On Nasdaq

EMMAC Life Sciences, one of Europe's largest cannabis companies, announced its plans to go public in the U.S.It will list on the Nasdaq exchange through a merger with Andina Acquisition Corp. III (NASDAQ: ANDA) (NASDAQ: ANDAW) (NASDAQ: ANDAU). EMMAC shareholders expect to collectively own a majority stake in the combined public company. EMMAC's Chairman Lorne Abony, CEO Antonio Costanzo, CFO Thomas Ellen, and COO Tom Rooke, will continue to lead the combined entity.Commenting on the news, Luke Weil, Chairman of Andina, told Benzinga that EMMAC is an "extremely attractive investment opportunity due to its leadership position in the large European market, which is driving strong revenue growth with a clear path to profitability."As a Nasdaq-listed company, EMMAC will provide U.S. investors with access to the largest vertically integrated pan-European footprint in the cannabis industry, he explained."EMMAC is the best-positioned company in European cannabis with low cost cultivation, EU-GMP manufacturing and processing, and an extensive import and distribution network in all key European markets," Abony added,The transition to a public company will further fuel the company's growth, support continued research into the medical benefits of cannabis, and solidify its leadership position in Europe."We look forward to partnering with Andina to capitalize on the large market opportunity we see ahead of us as we leverage our low-cost infrastructure, extensive footprint and diversified product portfolio to drive EMMAC's growth," he concluded.Lead image by Ilona Szentivanyi. Copyright: Benzinga.See more from Benzinga * Springbig, GrowFlow Partner Up On Compliance Services * LeafLink Financial Closes 0M In Debt Financing * Vertical Wellness Inks Deals With Tech-Holdings, GenCanna And Kathy Ireland 'To Weather Storm'(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

ANDAU Financial details

Company Rating
Neutral
Market Cap
405.29M
Income
-1.18M
Revenue
0
Book val./share
-0.83
Cash/share
3.82
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
-53.42
Forward P/E
-
PEG
3.24
P/S
-
P/B
2.42
P/C
2.91
P/FCF
-1320.79
Quick Ratio
15.56
Current Ratio
0.22
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.33
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-4%
ROE
-1%
ROC
-0.09%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
36.51M
Shs Float
18.73M
-
-
-
-
Target Price
-
52W Range
11.1-12.21
52W High
-7.5%
52W Low
+0.91%
RSI
-
Rel Volume
2.75
Avg Volume
409
Volume
1.12K
Perf Week
0%
Perf Month
0%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
0.001415
-
-
Volatility
0%, 0%
Prev Close
0%
Price
11.1
Change
0%

ANDAU Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2020-12-31

Metric History 2017-12-312018-12-312019-12-31 2020-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0000
Net income per share
000.510
Operating cash flow per share
00-0.12-0.07
Free cash flow per share
00-0.12-0.07
Cash per share
000.13.99
Book value per share
0032.061.45
Tangible book value per share
00.0132.061.45
Share holders equity per share
0032.061.45
Interest debt per share
00.0100
Market cap
134.78M134.78M34.98M36.74M
Enterprise value
134.8M134.89M34.63M36.54M
P/E ratio
-317.88K-9.12K19.850
Price to sales ratio
0000
POCF ratio
-21.37K-17.7K-87.65-144.45
PFCF ratio
-21.37K-17.7K-87.65-144.45
P/B Ratio
12.51K-33.72K0.327.35
PTB ratio
12.51K-33.72K0.327.35
EV to sales
0000
Enterprise value over EBITDA
-317.93K-9.13K19.65-32.06
EV to operating cash flow
-21.37K-17.72K-86.77-143.67
EV to free cash flow
-21.37K-17.72K-86.77-143.67
Earnings yield
000.050
Free cash flow yield
00-0.01-0.01
Debt to equity
2.06-26.6400
Debt to assets
0.310.3400
Net debt to EBITDA
-52.23-7.21-0.20.17
Current ratio
1.430.9863.010
Interest coverage
0000
Income quality
14.880.52-0.230
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
0000
Intangibles to total assets
0000
Capex to operating cash flow
0000
Capex to revenue
0000
Capex to depreciation
0000
Stock based compensation to revenue
0000
Graham number
0019.210
ROIC
-0.01-0.1400
Return on tangible assets
-0.01-0.050.020
Graham Net
0-0.010.11.45
Working capital
10.78K-4K354.88K198.19K
Tangible asset value
46.61K152.28K110.5M5M
Net current asset value
10.78K-4K354.88K-8.55M
Invested capital
2.06-26.6400
Average receivables
0000
Average payables
06.5K7.9K2.86K
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
-0.043.70.020
Capex per share
0000

Quarterly Fundamentals Overview

Last date of statement is 2021-06-30 for Q2

Metric History 2019-06-302019-12-312020-06-302020-12-31 2021-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
0.170.11-0.220-0.22
Operating cash flow per share
-0.02-0.01-0.03-0.01-0.04
Free cash flow per share
-0.02-0.01-0.03-0.01-0.04
Cash per share
0.130.10.053.863.82
Book value per share
31.0631.3130.891.4-0.83
Tangible book value per share
31.0631.3130.891.42.97
Share holders equity per share
31.0631.3130.891.4-0.83
Interest debt per share
00000
Market cap
34.98M35.83M36.55M37.98M36.73M
Enterprise value
34.54M35.47M36.38M37.78M36.67M
P/E ratio
14.9322.94-11.70-11.62
Price to sales ratio
00000
POCF ratio
-423.15-815.35-405.87-1.63K-264.19
PFCF ratio
-423.15-815.35-405.87-1.63K-264.19
P/B Ratio
0.320.320.337.6-12.46
PTB ratio
0.320.320.337.6-12.46
EV to sales
00000
Enterprise value over EBITDA
58.9690.86-46.59-33.14-46.41
EV to operating cash flow
-417.78-807.33-404-1.62K-263.77
EV to free cash flow
-417.78-807.33-404-1.62K-263.77
Earnings yield
0.020.01-0.020-0.02
Free cash flow yield
00000
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
-0.76-0.90.220.170.07
Current ratio
73.3863.010.2800.04
Interest coverage
00000
Income quality
-0.14-0.110.1200.18
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
10.778.8312.3402.03
ROIC
00-0.0100.23
Return on tangible assets
0.010-0.010-0.06
Graham Net
0.120.1-0.161.42.97
Working capital
533.68K354.88K-523.58K198.19K-2.08M
Tangible asset value
109.64M110.5M110.06M5M10.59M
Net current asset value
533.68K354.88K-523.58K-8.55M-2.95M
Invested capital
00000
Average receivables
00000
Average payables
8.72K6.55K2.86K00
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0.010-0.0100.27
Capex per share
00000

ANDAU Frequently Asked Questions

What is Andina Acquisition Corp. III stock symbol ?

Andina Acquisition Corp. III is a CO stock and trading under the symbol ANDAU

What is Andina Acquisition Corp. III stock quote today ?

Andina Acquisition Corp. III stock price is $11.1 today.

Is Andina Acquisition Corp. III stock public?

Yes, Andina Acquisition Corp. III is a publicly traded company.

Something similar

Top by Market Cap
Similar Market Cap